These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 39120316)

  • 1. A Novel Liquid Biopsy Method Based on Specific Combinations of Vesicular Markers Allows Us to Discriminate Prostate Cancer from Hyperplasia.
    Martorana E; Raciti G; Giuffrida R; Bruno E; Ficarra V; Ludovico GM; Suardi NR; Iraci N; Leggio L; Bussolati B; Grange C; Lorico A; Leonardi R; Forte S
    Cells; 2024 Jul; 13(15):. PubMed ID: 39120316
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum proteomic profiling can discriminate prostate cancer from benign prostates in men with total prostate specific antigen levels between 2.5 and 15.0 ng/ml.
    Ornstein DK; Rayford W; Fusaro VA; Conrads TP; Ross SJ; Hitt BA; Wiggins WW; Veenstra TD; Liotta LA; Petricoin EF
    J Urol; 2004 Oct; 172(4 Pt 1):1302-5. PubMed ID: 15371828
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Extracellular vesicles: the next generation of biomarkers for liquid biopsy-based prostate cancer diagnosis.
    Pang B; Zhu Y; Ni J; Thompson J; Malouf D; Bucci J; Graham P; Li Y
    Theranostics; 2020; 10(5):2309-2326. PubMed ID: 32089744
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Investigation on core-fucosylated prostate-specific antigen as a refined biomarker for differentiation of benign prostate hyperplasia and prostate cancer of different aggressiveness.
    Lang R; Rolny V; Leinenbach A; Karl J; Swiatek-de Lange M; Kobold U; Schrader M; Krause H; Mueller M; Vogeser M
    Tumour Biol; 2019 Mar; 41(3):1010428319827223. PubMed ID: 30907281
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Improved discrimination between prostatic carcinoma and benign prostatic hyperplasia by determination of free prostate-specific antigen percentage].
    Wolff JM; Borchers H; Boeckmann W; Habib FK; Jakse G
    Urologe A; 1997 May; 36(3):255-8. PubMed ID: 9265347
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical utility of a serum biomarker panel in distinguishing prostate cancer from benign prostate hyperplasia.
    Kiebish MA; Tekumalla P; Ravipaty S; Dobi A; Srivastava S; Wu W; Patil S; Friss T; Klotz A; Srinivasan A; Cullen J; Rosner IL; Ali A; Laszlo S; Petrovic M; Fleshner N; Garren J; Miller G; Mahaveer Chand N; Rodrigues LO; Granger E; Kellogg MD; Luan S; Diamandis E; Akmaev VR; Sarangarajan R; Bountra C; Freedland SJ; McLeod DG; Narain NR
    Sci Rep; 2021 Jul; 11(1):15052. PubMed ID: 34302010
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Differential diagnostic value of prostate-specific antigen in prostatic hyperplasia].
    Maksimov VA; Kamalov AA; Karpov VK; Riaboĭ AV; Prokhorov AV
    Urologiia; 2001; (2):37-40. PubMed ID: 11490716
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prostate specific antigen density: a method for differentiating prostate carcinoma from benign prostatic hypertrophy demonstrates ethnic variation.
    Martin AA; Clejan S
    J La State Med Soc; 1994 Apr; 146(4):163-71. PubMed ID: 7516401
    [No Abstract]   [Full Text] [Related]  

  • 9. [BIOMARKERS OF EARLY AND DIFFERENTIAL DIAGNOSIS OF PROSTATIC CANCER].
    Grygorenko VM; Danylets RO; Vikarchuk MV; Gorbahn LV; Klepko AV
    Klin Khir; 2017; (1):54-7. PubMed ID: 30272918
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Prognostic significance of prostate-specific antigen in defining indications for initial prostate biopsy].
    Popov SV; Guseinov RG; Skryabin ON; Orlov IN; Martov AG
    Urologiia; 2018 Jul; (3):92-97. PubMed ID: 30035426
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diagnostic significance of [-2]pro-PSA and prostate dimension-adjusted PSA-related indices in men with total PSA in the 2.0-10.0 ng/mL range.
    Ito K; Miyakubo M; Sekine Y; Koike H; Matsui H; Shibata Y; Suzuki K
    World J Urol; 2013 Apr; 31(2):305-11. PubMed ID: 22903772
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Significance of the PSA-concentration for the detection of prostate cancer].
    Stachon A
    Pathologe; 2005 Nov; 26(6):469-72. PubMed ID: 16195861
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discrimination of benign from malignant prostatic disease by selective measurements of single chain, intact free prostate specific antigen.
    Steuber T; Nurmikko P; Haese A; Pettersson K; Graefen M; Hammerer P; Huland H; Lilja H
    J Urol; 2002 Nov; 168(5):1917-22. PubMed ID: 12394676
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Additional aids in detection of prostate carcinomas? PSA-prostatic volume quotient, PSA-doubling time, age-dependent PSA reference values and PSA in urine].
    Pannek J; Brands FH
    Urologe A; 2000 Jul; 39(4):324-9. PubMed ID: 10957773
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Frequency of Unnecessarily Biopsies among Patients with Suspicion of Prostate Cancer in Syrian Men.
    Bachour DM; Chahin E; Al-Fahoum S
    Asian Pac J Cancer Prev; 2015; 16(14):5967-70. PubMed ID: 26320481
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Comment on Grond, A., M. Ostermann-Myrau: Benign and malignant diseases of the prostate].
    Grond A
    Versicherungsmedizin; 1995 Apr; 47(2):66-7. PubMed ID: 7539193
    [No Abstract]   [Full Text] [Related]  

  • 17. Human Kallikrein-2, Prostate Specific Antigen and Free- Prostate Specific Antigen in Combination to Discriminate Prostate Cancer from Benign Diseases in Syrian Patients.
    Bachour DM; Chahin E; Al-Fahoum S
    Asian Pac J Cancer Prev; 2015; 16(16):7085-8. PubMed ID: 26514494
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [PSA-based early detection of prostate cancer].
    Luboldt H; Rübben H
    Urologe A; 2000 Jan; 39(1):22-6. PubMed ID: 10663192
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Extracellular vesicles for liquid biopsy in prostate cancer: where are we and where are we headed?
    Minciacchi VR; Zijlstra A; Rubin MA; Di Vizio D
    Prostate Cancer Prostatic Dis; 2017 Sep; 20(3):251-258. PubMed ID: 28374743
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High grade intraepithelial neoplasia of prostate is associated with values of prostate specific antigen related parameters intermediate between prostate cancer and normal levels.
    Obralic N; Kulovac B
    Bosn J Basic Med Sci; 2011 Nov; 11(4):223-7. PubMed ID: 22117828
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.